About Caelus Health
Caelus Health is a company based in Heiloo (Netherlands) founded in 2014 by Max Nieuwdorp and Willem M De Vos. Caelus Health has raised $2.68 million across 1 funding round from investors including Johnson & Johnson Innovation and Life Sciences Fund Amsterdam. Caelus Health operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
- Headquarter Heiloo, Netherlands
- Founders Max Nieuwdorp, Willem M De Vos
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.68 M (USD)
in 1 rounds
-
Latest Funding Round
$2.68 M (USD), Series A
Jan 26, 2017
-
Investors
Johnson & Johnson Innovation
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Caelus Health
Caelus Health has successfully raised a total of $2.68M through 1 strategic funding round. The most recent funding activity was a Series A round of $2.68 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Caelus Health
Caelus Health has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Johnson & Johnson Innovation and Life Sciences Fund Amsterdam.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Caelus Health
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Caelus Health
Investment portfolio details for Caelus Health
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Caelus Health
Detailed financials for Caelus Health
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Caelus Health Comparisons
Peer comparison for Caelus Health
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Caelus Health
Caelus Health operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Caelus Health
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Caelus Health
Complete news archive for Caelus Health
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Caelus Health
Caelus Health was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Caelus Health is headquartered in Heiloo, Netherlands. It is registered at Heiloo, Noord-holland, Netherlands.
Luc Sterkman is the current CEO of Caelus Health.
Caelus Health is a funded company, having raised a total of $2.68M across 1 funding round to date.
Developer of microbiota-based products to address cardiometabolic disorders. The company leverages in-depth knowledge of the microbiome to create pipeline of products which include CH-0106 and CH-0402 to treat Type 2 diabetes and CH-0701 drug intervention is based on FMT in Cancer cachexia.
Caelus Health's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Caelus Health has 2 investors. Key investors include Johnson & Johnson Innovation, and Life Sciences Fund Amsterdam.